Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
| ▸ | DHFR | P00374 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9014687 | 1.00 | CA2 (0.56) | CA2CA1CA12CA9LMNA | |
| SCHEMBL14497757 | 0.87 | CA2 (0.52) | CA2CA1CA12CA9LMNA | |
| SCHEMBL887827 | 0.87 | CA2 (0.52) | CA2CA1CA12CA9LMNA | |
| SCHEMBL13338129 | 0.87 | CA2 (0.52) | CA2CA1CA12CA9LMNA | |
| SCHEMBL8726202 | 0.84 | CA2 (0.46) | CA2CA1CA12CA9LMNA | |
| SCHEMBL7902186 | 0.84 | FOLH1 (0.58) | LMNAFOLH1GMNNALDH1A1CYP2D6 | |
| SCHEMBL4458797 | 0.84 | FOLH1 (0.58) | LMNAFOLH1GMNNALDH1A1CYP2D6 | |
| SCHEMBL27564186 | 0.83 | CA2 (0.75) | CA2CA1CA12CA9LMNA | |
| Hydrochloric Acid SCHEMBL7903946 | 0.82 | FOLH1 (0.57) | LMNAFOLH1GMNNALDH1A1CYP2D6 | |
| SCHEMBL7900436 | 0.82 | KMT2A (0.69) | LMNAFOLH1GMNNALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43586-E1 | Antibodies to prostate-specific membrane antigen | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-08-14 | — | — | US | disclosed |
| CN-102099045-A | Attenuated oncolytic paramyxoviruses encoding avian cytokines | BAYER SCHERING PHARMA AG | 2011-06-15 | — | — | CN | disclosed |
| EP-2292246-A1 | Recombinant Newcastle Disease Virus | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-03-09 | — | — | EP | disclosed |
| EP-0668777-B2 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN | SLOAN KETTERING INST CANCER (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20110020282-A1 | RECOMBINANT NEWCASTLE DISEASE VIRUS | BEIER RUDOLF | 2011-01-27 | — | — | US | disclosed |
| US-20100310452-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH | 2010-12-09 | — | — | US | disclosed |
| US-20100303715-A1 | Prostate-specific membrane antigen and uses thereof | ISRAELI RON S | 2010-12-02 | — | — | US | disclosed |
| CN-101875919-A | Recombinant newcastle disease virus | BAYER SCHERING PHARMA AG | 2010-11-03 | — | — | CN | disclosed |
| EP-2237790-A1 | ATTENUATED ONCOLYTIC PARAMYXOVIRUSES ENCODING AVIAN CYTOKINES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-13 | — | — | EP | disclosed |
| US-20100092430-A1 | ATTENUATED ONCOLYTIC PARAMYXOVIRUSES ENCODING AVIAN CYTOKINES | BAYER SCHERING PHARMA AG (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-1996026272-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1996-08-29 | — | — | WO | disclosed |
| US-5538866-A | IMMUNOASSAY; MEDICAL DIAGNOSIS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1996-07-23 | — | — | US | disclosed |
| EP-0696270-A1 | 4-AMINO-FLUOROBENZAMIDES AND THEIR USE AS CYTOTOXIC PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-02-14 | — | — | EP | disclosed |
| EP-0668777-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN | Sloan-Kettering Institute For Cancer Research (US) | 1995-08-30 | — | — | EP | disclosed |
| WO-1994025429-A1 | 4-AMINO-FLUOROBENZAMIDES AND THEIR USE AS CYTOTOXIC PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1994-11-10 | — | — | WO | disclosed |
| US-5359120-A | Reacting nitrogen mustard compounds with amino acid or oligopeptide compounds | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1994-10-25 | — | — | US | disclosed |
| WO-1994009820-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1994-05-11 | — | — | WO | disclosed |
| EP-0433360-B1 | IMPROVEMENTS RELATING TO THE PRODUCTION OF PRODRUGS | CANCER RES CAMPAIGN TECH (GB) | 1994-03-23 | — | — | EP | disclosed |
| EP-0433360-A1 | IMPROVEMENTS RELATING TO THE PRODUCTION OF PRODRUGS. | CANCER RES CAMPAIGN TECH (GB) | 1991-06-26 | — | — | EP | disclosed |
| WO-1990002729-A1 | IMPROVEMENTS RELATING TO THE PRODUCTION OF PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1990-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310452-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | KLK3, ACP3, FOLH1 | CA2 1265/4885CA1 462/4885CA12 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.